Q-omics provides the consensus-scored SPECC1L-ADORA2A profile across patient tissues and cancer cell-line models. SPECC1L-ADORA2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPECC1L-ADORA2A is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, SPECC1L-ADORA2A RNA expression shows 16,213 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where SPECC1L-ADORA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPECC1L-ADORA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPECC1L-ADORA2A survival associations across molecular data types. SPECC1L-ADORA2A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPECC1L-ADORA2A RNA expression–survival associations across cancer types. High SPECC1L-ADORA2A expression shows unfavorable associations in ACC, LUSC, KICH and KIRP, but favorable associations in STAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPECC1L-ADORA2A RNA expression.
This table summarizes SPECC1L-ADORA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SPECC1L-ADORA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPECC1L-ADORA2A shows lower tumor expression in THCA and COAD and higher tumor expression in KIRC, HNSC, ESCA and CHOL. The THCA box plot shows higher SPECC1L-ADORA2A RNA expression in normal versus tumor tissue (log2 FC = −0.033, t-test p < 0.001).
This table shows molecular features associated with SPECC1L-ADORA2A in patient tissues and cancer cell lines. In patient samples, SPECC1L-ADORA2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPECC1L-ADORA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
